Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma

NCT02876978 is registered in ClinicalTrials.gov with CARsgen Therapeutics Co., Ltd. as lead sponsor.

NCT NCT02876978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02876978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma
Lead sponsor
CARsgen Therapeutics Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
March 31, 2016
Completion date
April 30, 2019
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung squamous cell carcinoma